ArticlePediatric nephrology (Berlin, Germany)2013
Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy.
Article in Pediatric nephrology (Berlin, Germany), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.Renal failure · 2020Trial
- Cyclophosphamide Toxicity in Pediatric Nephrotic Syndrome Patient: A Case Report and Literature Review.Current drug safety · 2024Review
- Clinical and Histopathologic Characteristics of Pediatric Patients With Primary Membranous Nephropathy.Kidney international reports · 2023Article
- Clinicopathologic features of non-lupus membranous nephropathy in a pediatric population.Pediatric nephrology (Berlin, Germany) · 2022Review
- Pediatric membranous nephropathy: In the novel antigens era.Frontiers in immunology · 2022Review
- Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia.Pediatric nephrology (Berlin, Germany) · 2021Article
- Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era.Pediatric nephrology (Berlin, Germany) · 2021Review
- How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy.Frontiers in immunology · 2021Review
- Profile of Indian Patients With Membranous Nephropathy.Kidney international reports · 2020Article
- Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN).Kidney international reports · 2019Article
- Proteinuria in a patient with Graves' disease: Answers.Pediatric nephrology (Berlin, Germany) · 2019Article
- Proteinuria in a patient with Graves' disease: Questions.Pediatric nephrology (Berlin, Germany) · 2019Article
- Genetics of membranous nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2018Review
- Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.Pediatric nephrology (Berlin, Germany) · 2018Article
- M-type phospholipase APediatric nephrology (Berlin, Germany) · 2017Article
- Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy.BioMed research international · 2017Review
- Article
- Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype.Virchows Archiv : an international journal of pathology · 2015Article
- Membranous nephropathy: not just a disease for adults.Pediatric nephrology (Berlin, Germany) · 2015Review
- The Clinical Profile and Long-Term Outcome of Children with Membranous Nephropathy, and the Evaluation of Anti-Phospholipase A2 Receptor Antibody Immunohistochemistry in Kidney Biopsy.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMembranous glomerulopathy, though typically a disease of adults, does occur in children. Antiphospholipase A2 receptor (PLA2R) autoantibodies have recently been implicated as a causative agent in most cases of adult primary (idiopathic) membranous glomerulopathy. PLA2R staining of renal biopsies in two recent large case series of adults with primary membranous glomerulopathy showed a sensitivity of approximately 75 % for detecting primary membranous glomerulopathy. To our knowledge, this is the largest study of its kind to assess PLA2R staining in a pediatric population.
methodsForty-one consecutive cases of pediatric membranous glomerulopathy were identified from our database, and clinical follow-up was performed to confirm primary membranous glomerulopathy. Twenty-two patients met inclusion criteria and are the subject of this report.
resultsGranular, capillary loop immunofluorescence staining for immunoglobulin G (IgG) was present in 100 % of patients, and C3 staining was present in 77 %. PLA2R staining was identified in ten patients, providing a sensitivity of 45 % [confidence interval (CI) 25-67 %]. Bovine serum albumin staining was performed in all PLA2R-negative cases and showed no positivity. Morphologic findings associated with negative PLA2R staining included segmental membranous lesions, mesangial and subendothelial deposits, C1q and "full-house" staining, and lower-stage lesions by electron microscopy. At 38 months' average follow-up, all patients were still considered as having primary membranous glomerulopathy, with none developing a clinically detectable secondary etiology.
conclusionsPLA2R staining sensitivity is much lower in the pediatric than the adult primary membranous glomerulopathy population. This finding suggests a more diverse and currently incompletely described set of etiologies for this disease in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.